As a cancer marker, as we have shown in this study, PD-L1 expression is significantly associated with the survival of cancer patients [15,20,21,22], and the immunohistochemical expression of PD-L1 can be employed to select the patients who will be subjected to anti-PD-L1 therapy [33]. This evidence concerns the gene CD274 and cancer.